Liposarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:36:22 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Liposarcoma metastatic – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study of Trabectedin alone versus Trabectedin with tTF-NGR combination therapy in adults with metastatic or refractory soft tissue sarcoma who failed first-line treatment https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ Wed, 29 Apr 2026 14:59:55 +0000 https://clinicaltrials.eu/trial/study-on-trabectedin-and-ttf-ngr-for-patients-with-metastatic-or-refractory-soft-tissue-sarcoma/ This clinical trial studies a treatment for soft tissue sarcoma, a type of cancer that develops in soft tissues like muscles and fat. The study focuses on patients whose cancer has spread to other parts of the body (metastatic) or who did not respond well to previous treatments. The trial compares two treatment approaches: one using only trabectedin (a chemotherapy medication) and another combining trabectedin with tTF-NGR (an experimental drug).

The study aims to determine if adding tTF-NGR to standard trabectedin treatment helps keep the cancer under control for a longer time. Both medications are given through an intravenous infusion directly into the bloodstream. The experimental drug tTF-NGR is designed to concentrate the chemotherapy medication inside the tumor.

During the study, participants receive treatment for up to 360 days. Some patients will receive only trabectedin, while others will receive both trabectedin and tTF-NGR. Regular medical examinations and imaging tests will be performed to monitor how the cancer responds to the treatment. The study focuses on patients whose tumors show a specific characteristic called CD13 positivity, which is determined through laboratory testing.

]]> Study on PF-07220060, Letrozole, and Fulvestrant for Patients with Advanced Breast Cancer, Prostate Cancer, and Other Solid Tumors https://clinicaltrials.eu/trial/study-on-pf-07220060-letrozole-and-fulvestrant-for-patients-with-advanced-breast-cancer-prostate-cancer-and-other-solid-tumors/ Wed, 29 Apr 2026 14:28:19 +0000 https://clinicaltrials.eu/trial/study-on-pf-07220060-letrozole-and-fulvestrant-for-patients-with-advanced-breast-cancer-prostate-cancer-and-other-solid-tumors/ This clinical trial is focused on studying advanced solid tumors, which are types of cancer that have spread beyond their original location. The study involves several types of cancer, including breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, colorectal cancer (CRC), and liposarcoma. It also includes tumors with specific genetic changes known as CDK4 or CCND1 amplification. The main treatment being tested is a new medication called PF-07220060, which is being evaluated both on its own and in combination with other treatments. These other treatments include letrozole, fulvestrant, and enzalutamide, which are medications commonly used in treating certain types of cancer.

The purpose of the study is to assess the safety and effectiveness of PF-07220060 in treating these advanced cancers. Participants will receive the medication in tablet form, taken by mouth, and in some cases, it will be combined with other cancer treatments. The study will also explore how the body processes the medication and how it affects the tumors. Some participants will receive a placebo, which is a substance with no active medication, to help compare the effects of the treatment.

The study will be conducted in different parts, each focusing on specific types of cancer and treatment combinations. Participants will be monitored for safety and any side effects, and the study will help determine the best dose of PF-07220060 to use in future research. The trial is expected to continue until 2026, with the goal of finding new and effective ways to treat advanced solid tumors.

]]> Study of Pemigatinib and Retifanlimab for Patients with Advanced Dedifferentiated Liposarcoma https://clinicaltrials.eu/trial/study-of-pemigatinib-and-retifanlimab-for-patients-with-advanced-dedifferentiated-liposarcoma/ Wed, 29 Apr 2026 14:26:43 +0000 https://clinicaltrials.eu/trial/study-of-pemigatinib-and-retifanlimab-for-patients-with-advanced-dedifferentiated-liposarcoma/ This clinical trial is focused on studying a type of cancer called dedifferentiated liposarcoma, which is a rare form of cancer that develops in fat cells. The study is testing two treatments: Pemigatinib, which is taken as a tablet, and Retifanlimab (also known by its code name INCMGA00012), which is given as a solution through an intravenous infusion. The purpose of the study is to evaluate the potential benefits of these treatments for patients with advanced dedifferentiated liposarcoma.

Participants in the study will receive either the active treatments or a placebo. The study will monitor the progression of the disease over a period of time, looking at how long patients live without the disease getting worse and how their bodies respond to the treatments. The study will also assess the overall survival of patients, which means the length of time patients live from the start of the treatment. Additionally, the study will track any side effects or adverse events that occur during the treatment period.

The trial will also evaluate changes in patients’ quality of life and their ability to perform daily activities. This will be done using a questionnaire designed to measure these aspects. The study aims to provide valuable information on the effectiveness and safety of Pemigatinib and Retifanlimab in treating advanced dedifferentiated liposarcoma, potentially leading to improved treatment options for patients with this condition.

]]>